Literature DB >> 15235805

Pathological entity of dementia with Lewy bodies and its differentiation from Alzheimer's disease.

Wami Marui1, Eizo Iseki, Masanori Kato, Hiroyasu Akatsu, Kenji Kosaka.   

Abstract

We reclassified the pathological subtypes of dementia with Lewy bodies (DLB), based on both Lewy pathology and Alzheimer pathology, to clarify the pathological entity of DLB and the boundary between DLB and Alzheimer's disease (AD) in autopsied cases, using both pathological and immunohistochemical methods. DLB was classified as either limbic type or neocortical type according to the degree of Lewy pathology including Lewy bodies (LB) and LB-related neurites by our staging, and was classified as pure form, common form or AD form according to the degree of Alzheimer pathology including neurofibrillary tangles (NFT) and amyloid deposits by Braak staging. These combined subtypes were lined up on a spectrum, not only with Lewy pathology but also with other DLB-related pathologies including Alzheimer pathology, neuronal loss in the substantia nigra, spongiform change in the transentorhinal cortex and LB-related neurites in the CA2-3 region. In contrast, the Lewy pathology of AD did not meet the stages of Lewy pathology in DLB, and there were scarcely any similarities in other DLB-related pathologies between AD and DLB. In addition, the Lewy pathology of AD had characteristics different from that of DLB, including the coexistence rate of LB with NFT, and the immunohistochemical and immunoelectron microscopic findings of LB and LB-related neurites. These findings suggest that DLB is a distinctive pathological entity that can be differentiated from AD, although it shows some pathological subtypes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15235805     DOI: 10.1007/s00401-004-0869-4

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  21 in total

1.  Differential nigral expression of bcl-2 protein family in the pure and common forms of Dementia with Lewy bodies: relevance for dopaminergic neuronal vulnerability.

Authors:  M Saldaña; E Aguilar; M Bonastre; C Marin
Journal:  J Neural Transm (Vienna)       Date:  2007-07-04       Impact factor: 3.575

2.  Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies.

Authors:  Lih-Fen Lue; Douglas G Walker; Charles H Adler; Holly Shill; Hung Tran; Haruhiko Akiyama; Lucia I Sue; John Caviness; Marwan N Sabbagh; Thomas G Beach
Journal:  Brain Pathol       Date:  2012-04-12       Impact factor: 6.508

3.  Sequence variants in eukaryotic translation initiation factor 4-gamma (eIF4G1) are associated with Lewy body dementia.

Authors:  Shinsuke Fujioka; Christina Sundal; Audrey J Strongosky; Monica Case Castanedes; Rosa Rademakers; Owen A Ross; Carles Vilariño-Güell; Matthew J Farrer; Zbigniew K Wszolek; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2012-11-04       Impact factor: 17.088

4.  Most cases with Lewy pathology in a population-based cohort adhere to the Braak progression pattern but 'failure to fit' is highly dependent on staging system applied.

Authors:  David G Coughlin; Helen Petrovitch; Lon R White; Joseph Noorigian; Kamal H Masaki; G Webster Ross; John E Duda
Journal:  Parkinsonism Relat Disord       Date:  2019-03-28       Impact factor: 4.891

5.  Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy.

Authors:  Hirotake Uchikado; Wen-Lang Lin; Michael W DeLucia; Dennis W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2006-07       Impact factor: 3.685

Review 6.  Neuropsychological assessment of patients with dementing illness.

Authors:  Julie A Fields; Tanis J Ferman; Bradley F Boeve; Glenn E Smith
Journal:  Nat Rev Neurol       Date:  2011-11-01       Impact factor: 42.937

7.  APOE DNA methylation is altered in Lewy body dementia.

Authors:  Jessica Tulloch; Lesley Leong; Sunny Chen; C Dirk Keene; Steven P Millard; Andrew Shutes-David; Oscar L Lopez; Julia Kofler; Jeffrey A Kaye; Randy Woltjer; Peter T Nelson; Janna H Neltner; Gregory A Jicha; Douglas Galasko; Eliezer Masliah; James B Leverenz; Chang-En Yu; Debby Tsuang
Journal:  Alzheimers Dement       Date:  2018-03-12       Impact factor: 21.566

8.  Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer's disease dementia.

Authors:  Michel J Grothe; Christina Schuster; Florian Bauer; Helmut Heinsen; Johannes Prudlo; Stefan J Teipel
Journal:  J Neurol       Date:  2014-07-25       Impact factor: 4.849

9.  Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease.

Authors:  Shinji Higashi; Darren J Moore; Ryoko Yamamoto; Michiko Minegishi; Kiyoshi Sato; Takashi Togo; Omi Katsuse; Hirotake Uchikado; Yoshiko Furukawa; Hiroaki Hino; Kenji Kosaka; Piers C Emson; Keiji Wada; Valina L Dawson; Ted M Dawson; Heii Arai; Eizo Iseki
Journal:  J Neuropathol Exp Neurol       Date:  2009-09       Impact factor: 3.685

10.  Critical appraisal of pathology transmission in the α-synuclein fibril model of Lewy body disorders.

Authors:  Negin Nouraei; Daniel M Mason; Kristin M Miner; Michael A Carcella; Tarun N Bhatia; Benjamin K Dumm; Dishaben Soni; David A Johnson; Kelvin C Luk; Rehana K Leak
Journal:  Exp Neurol       Date:  2017-10-19       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.